MedTrace Logo

Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema

NCT01194674 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-07-31

Study results available
· View outcomes & findings →

Summary

The objective of this study is to investigate the safety and efficacy of microplasmin as a treatment for uveitic macular edema.

Conditions

  • Uveitis

Interventions

DRUG

Microplasmin

Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • Hatice Nida Sen, MD, MHSc · National Institutes of Health (NIH)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01194674 on ClinicalTrials.gov